Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods
- PMID: 33685409
- PMCID: PMC7941925
- DOI: 10.1186/s12885-021-07948-9
Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods
Abstract
Background: We quantified the elusive effects of putative factors on the clinical course of early hepatocellular carcinoma (HCC) after primary surgical or nonsurgical curative treatment.
Methods: Patients with newly diagnosed early HCC who received surgical resection (SR) or percutaneous radiofrequency ablation (RFA) with or without transcatheter arterial chemoembolization (TACE) from January 2003 to December 2016 were enrolled. The cumulative overall survival (OS) and disease-free survival (DFS) rates were compared. A polytomous logistic regression was used to estimate factors for early and late recurrence. Independent predictors of OS were identified using Cox proportional hazard regression.
Results: One hundred twenty-five patients underwent SR, and 176 patients underwent RFA, of whom 72 were treated with TACE followed by RFA. Neither match analysis based on propensity score nor multiple adjustment regression yielded a significant difference in DFS and OS between the two groups. Multivariate analysis showed high AFP (> 20 ng/mL), and multinodularity significantly increased risk of early recurrence (< 1 year). In contrast, hepatitis B virus, hepatitis C virus and multinodularity were significantly associated with late recurrence (> 1 year). Multivariate Cox regression with recurrent events as time-varying covariates identified older age (HR = 1.55, 95% CI:1.01-2.36), clinically significant portal hypertension (CSPH) (HR = 1.97, 95% CI:1.26-3.08), early recurrence (HR = 6.62, 95% CI:3.79-11.6) and late recurrence (HR = 3.75, 95% CI:1.99-7.08) as independent risk factors of mortality. A simple risk score showed fair calibration and discrimination in early HCC patients after primary curative treatment. In the Barcelona Clinic Liver Cancer (BCLC) stage A subgroup, SR significantly improved DFS compared to RFA with or without TACE.
Conclusion: Host and tumor factors rather than the initial treatment modalities determine the outcomes of early HCC after primary curative treatment. Statistical models based on recurrence types can predict early HCC prognosis but further external validation is necessary.
Keywords: Early hepatocellular carcinoma; Prognosis; Propensity score matching; Radiofrequency ablation; Surgical resection; Transcatheter arterial chemoembolization.
Conflict of interest statement
Ming-Jeng Kuo, Lein-Ray Mo, Chi-Ling Chen declare that they have no conflict of interest.
Figures



Similar articles
-
Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.BMC Gastroenterol. 2020 Apr 10;20(1):99. doi: 10.1186/s12876-020-01235-w. BMC Gastroenterol. 2020. PMID: 32272898 Free PMC article.
-
Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion.World J Gastroenterol. 2017 Nov 7;23(41):7415-7424. doi: 10.3748/wjg.v23.i41.7415. World J Gastroenterol. 2017. PMID: 29151695 Free PMC article.
-
Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.J Gastroenterol Hepatol. 2016 Feb;31(2):442-9. doi: 10.1111/jgh.13077. J Gastroenterol Hepatol. 2016. PMID: 26259976
-
Trans-arterial chemoembolization + radiofrequency ablation versus surgical resection in hepatocellular carcinoma - A meta-analysis.Eur J Surg Oncol. 2020 May;46(5):763-771. doi: 10.1016/j.ejso.2020.01.004. Epub 2020 Jan 7. Eur J Surg Oncol. 2020. PMID: 31937433 Review.
-
Comparison of liver resection and radiofrequency ablation in long-term survival among patients with early-stage hepatocellular carcinoma: a meta-analysis of randomized trials and high-quality propensity score-matched studies.World J Surg Oncol. 2024 Feb 19;22(1):56. doi: 10.1186/s12957-024-03330-8. World J Surg Oncol. 2024. PMID: 38369480 Free PMC article.
Cited by
-
Impact of Metabolic Dysfunction-Associated Fatty Liver Disease on the Prognosis of Patients With Hepatocellular Carcinoma After Radical Resection: A Retrospective Study.Cureus. 2024 Dec 7;16(12):e75302. doi: 10.7759/cureus.75302. eCollection 2024 Dec. Cureus. 2024. PMID: 39781154 Free PMC article.
-
Transarterial Chemoembolization Combined With Radiofrequency Ablation Versus Hepatectomy for Hepatocellular Carcinoma: A Meta-Analysis.Front Surg. 2022 Jul 11;9:948355. doi: 10.3389/fsurg.2022.948355. eCollection 2022. Front Surg. 2022. PMID: 35898584 Free PMC article. Review.
-
Sex Differences in the Impact of Metabolic Dysfunction-associated Fatty Liver Disease on the of Patients with Hepatocellular Carcinoma After Radical Resection.J Cancer. 2023 Apr 17;14(7):1107-1116. doi: 10.7150/jca.83779. eCollection 2023. J Cancer. 2023. PMID: 37215444 Free PMC article.
-
Effect of coronavirus disease 2019 on diagnosis and treatment of hepatocellular carcinoma: a systematic review.Explor Target Antitumor Ther. 2023;4(5):1039-1058. doi: 10.37349/etat.2023.00179. Epub 2023 Oct 26. Explor Target Antitumor Ther. 2023. PMID: 38023991 Free PMC article.
-
Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis.Ann Surg Oncol. 2022 Feb 22. doi: 10.1245/s10434-022-11454-y. Online ahead of print. Ann Surg Oncol. 2022. PMID: 35192156
References
-
- Chan AWH, Zhong J, Berhane S, Toyoda H, Cucchetti A, Shi K, Tada T, Chong CCN, Xiang BD, Li LQ, et al. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol. 2018;69(6):1284–1293. doi: 10.1016/j.jhep.2018.08.027. - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous